Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: A randomized controlled trial

Abstract

The objective of this study was to compare the efficacy of flutamide and cyproterone acetate in the treatment of hirsutism.

Twenty-two women with idiopathic hirsutism were randomized to receive either flutamide or cyproterone acetate. Each patient underwent a complete gynecological examination as well as an endocrinological profile and hematological, hepatic and renal function analyses. Hirsutism scores were determined using a modified Ferriman—Gallwey scoring system. These tests were then repeated at 3 and 9 months of therapy. Eleven patients received 250mg of flutamide twice daily and 11 patents received 100 mg of cyproterone acetate on days 5-14 of the menstrual cycle.

Ferriman—Gallwey scores were decreased significantly in both groups at the end of 9 months. There was a trend towards a better response with flutamide, that did not achieve significance. Another significant difference was the increased sex hormone-binding globulin in both groups. A statistically significant decrease was also observed for the levels of testosterone on both drugs. No subject withdrew from the study dire to a side-effect.

The data suggest that both flutamide and cyproterone acetate were similarly effective in treatement of hirsutism, and that the pure antiandrogen flutamide is a safe, well-tolerated and effective alternative in treatment.

Key Words:

• Cyproterone Acetate
• Idiopathic Hirsutism
• Antiandrogenic Drugs
• Flutamide
• Female Hypekandkogenism